- Home
- NA vs CRVO Comparison
NA vs CRVO Comparison
Compare NA & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | CRVO |
|---|---|---|
| Founded | 2019 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.0M | 78.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | NA | CRVO |
|---|---|---|
| Price | $3.72 | $7.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 45.1K | ★ 58.0K |
| Earning Date | 08-15-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,369,693.00 | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $1.92 |
| 52 Week High | $31.48 | $16.94 |
Technical Indicators
Market Signals| Indicator | NA | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 37.66 |
| Support Level | $3.12 | $6.90 |
| Resistance Level | $3.90 | $8.22 |
| Average True Range (ATR) | 0.26 | 0.51 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 75.52 | 14.10 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.